A Clinical Observation of Bushen Jiangu Capsule for Primary Osteoprosis with

Objective:To study the therapeutic effect and safety of Bushen Jiangu Capsule (BJC)for primary osteoporosis (PO)with kidney-yin and liver-yin deficiency syndrome.Methods:Double -blind double -mimic randomized control trial, single - blind randomized control trial and open treatment were adopted. Three hundred and thirty cases of PO were allocated to BJC treatment group (Group A), BJC open treatment group (Group B) and Gusongbao control group (Group C). Results: The total effective rate and the remarkably effective rate were 89.5%and 47.6%in Group A, 91. 1 %and 47. 8%in Group B and 80. 8%and 22. 5%in Group C respectively. The differences of the above indexes between Group A and Group C were significant. The differences of symptom score between Group A and Group B were significant. The improvement of symptoms and femur bone mineral density in Group A were superior to Group B. No obvious adverse actions were found. Con clusion: BJC in the test dose is an effective and safe drug for PO.